• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病毒蛋白酶:一个新兴的治疗靶点。

Viral proteases: an emerging therapeutic target.

作者信息

Korant B D

机构信息

Central Research Department, DuPont Experimental Station, Wilmington, Delaware.

出版信息

Crit Rev Biotechnol. 1988;8(2):149-57. doi: 10.3109/07388558809150543.

DOI:10.3109/07388558809150543
PMID:3067861
Abstract

Only a few viral diseases are presently treatable because of our limited knowledge of specific viral target molecules. An attractive class of viral molecules toward which chemotherapeutic agents could be aimed are proteases coded by some virus groups such as retro- or picornaviruses (poliomyelitis, common cold virus). The picornavirus enzymes were discovered first, and they have now been characterized by a combination of molecular-genetic and biochemical approaches. Several laboratories have expressed the picornaviral enzymes in heterologous systems and have reported proteolytic activity, as well as the high cleavage fidelity diagnostic of the viral proteases. After dealing with several technical difficulties often encountered in standard genetic engineering approaches, one viral protease is now available to us in quantity and is amendable to mutagenic procedures. The initial outcome of the mutagenesis studies has been the confirmation of our earlier work with inhibitors, which suggested a cysteine active-site class. There is a clustering of active-site residues which may be unique to these viruses. The requirement for an active-site cysteine-histidine pair in combination with detailed information on the viral cleavage sites has permitted design of selective inhibitors with attractive antiviral properties. Future goals include investigation of the structural basis for selective processing and application of the cleavage specificity to general problems in genetic engineering.

摘要

由于我们对特定病毒靶分子的了解有限,目前只有少数病毒性疾病可以得到治疗。一类有吸引力的可作为化学治疗药物作用靶点的病毒分子是某些病毒组编码的蛋白酶,如逆转录病毒或小核糖核酸病毒(脊髓灰质炎病毒、普通感冒病毒)。小核糖核酸病毒酶最早被发现,现在已通过分子遗传学和生物化学方法的结合进行了表征。几个实验室已在异源系统中表达了小核糖核酸病毒酶,并报告了其蛋白水解活性以及病毒蛋白酶特有的高切割保真度。在解决了标准基因工程方法中经常遇到的几个技术难题后,现在我们可以大量获得一种病毒蛋白酶,并且它适合进行诱变程序。诱变研究的初步结果证实了我们早期使用抑制剂的工作,这表明其活性位点属于半胱氨酸类。活性位点残基存在聚集现象,这可能是这些病毒所特有的。对活性位点半胱氨酸 - 组氨酸对的需求,结合有关病毒切割位点的详细信息,使得设计具有诱人抗病毒特性的选择性抑制剂成为可能。未来的目标包括研究选择性加工的结构基础,以及将切割特异性应用于基因工程中的一般问题。

相似文献

1
Viral proteases: an emerging therapeutic target.病毒蛋白酶:一个新兴的治疗靶点。
Crit Rev Biotechnol. 1988;8(2):149-57. doi: 10.3109/07388558809150543.
2
[Role of proteolysis in the reproduction of animal and human viruses and the antiviral activity of protease inhibitors].[蛋白水解在动物和人类病毒繁殖中的作用以及蛋白酶抑制剂的抗病毒活性]
Usp Sovrem Biol. 1982 May-Jun;93(3):352-62.
3
[Molecular mechanisms of proteolytic processing of viral proteins and the problem of antiviral chemotherapy and vaccine design].
Mol Biol (Mosk). 1988 May-Jun;22(3):581-600.
4
Proteolysis is a key process in virus replication.蛋白质水解是病毒复制中的一个关键过程。
Essays Biochem. 1992;27:1-16.
5
Viral proteins and site-specific cleavage.
Acta Biol Med Ger. 1981;40(10-11):1481-8.
6
Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections.蛋白酶抑制剂作为治疗小核糖核酸病毒感染的潜在抗病毒药物。
Prog Drug Res. 1999;52:197-219. doi: 10.1007/978-3-0348-8730-4_5.
7
A single amino acid change in protein synthesis initiation factor 4G renders cap-dependent translation resistant to picornaviral 2A proteases.蛋白质合成起始因子4G中的单个氨基酸变化使依赖帽子结构的翻译对微小核糖核酸病毒2A蛋白酶具有抗性。
Biochemistry. 1996 Dec 10;35(49):15726-33. doi: 10.1021/bi961864t.
8
Antivirals other than for HIV therapy.用于除HIV治疗之外的抗病毒药物。
Adv Pediatr. 2000;47:335-94.
9
Interactions between a viral protease and cystatins.病毒蛋白酶与半胱氨酸蛋白酶抑制剂之间的相互作用。
Biol Chem Hoppe Seyler. 1988 May;369 Suppl:281-6.
10
Inhibiting viral proteases: challenges and opportunities.抑制病毒蛋白酶:挑战与机遇
Biopolymers. 2002;66(2):101-14. doi: 10.1002/bip.10230.

引用本文的文献

1
Human salivary cystatin S. Cloning, sequence analysis, hybridization in situ and immunocytochemistry.人唾液胱抑素S。克隆、序列分析、原位杂交和免疫细胞化学。
Biochem J. 1991 Sep 15;278 ( Pt 3)(Pt 3):627-35. doi: 10.1042/bj2780627.
2
A rapid method for determination of endoproteinase substrate specificity: specificity of the 3C proteinase from hepatitis A virus.一种测定内蛋白酶底物特异性的快速方法:甲型肝炎病毒3C蛋白酶的特异性
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11510-4. doi: 10.1073/pnas.88.24.11510.